{"id":19740,"date":"2024-02-23T01:00:06","date_gmt":"2024-02-23T06:00:06","guid":{"rendered":"https:\/\/sliceofhealthcare.com\/?p=19740"},"modified":"2024-02-23T01:39:20","modified_gmt":"2024-02-23T06:39:20","slug":"gilead-acquires-cymabay-in-4-3-billion-deal","status":"publish","type":"post","link":"https:\/\/sliceofhealthcare.com\/gilead-acquires-cymabay-in-4-3-billion-deal\/","title":{"rendered":"Gilead Acquires CymaBay in $4.3 Billion Deal"},"content":{"rendered":"\t\t<div data-elementor-type=\"wp-post\" data-elementor-id=\"19740\" class=\"elementor elementor-19740\" data-elementor-post-type=\"post\">\n\t\t\t\t\t\t<section class=\"elementor-section elementor-top-section elementor-element elementor-element-53265ad elementor-section-boxed elementor-section-height-default elementor-section-height-default wpr-particle-no wpr-jarallax-no wpr-parallax-no wpr-sticky-section-no\" data-id=\"53265ad\" data-element_type=\"section\">\n\t\t\t\t\t\t<div class=\"elementor-container elementor-column-gap-default\">\n\t\t\t\t\t<div class=\"elementor-column elementor-col-100 elementor-top-column elementor-element elementor-element-b1fd0d8\" data-id=\"b1fd0d8\" data-element_type=\"column\">\n\t\t\t<div class=\"elementor-widget-wrap elementor-element-populated\">\n\t\t\t\t\t\t<div class=\"elementor-element elementor-element-219a45b elementor-widget elementor-widget-heading\" data-id=\"219a45b\" data-element_type=\"widget\" data-widget_type=\"heading.default\">\n\t\t\t\t<div class=\"elementor-widget-container\">\n\t\t\t\t\t<h2 id=\"key-highlights\" class=\"elementor-heading-title elementor-size-default\">Key Highlights<\/h2>\t\t\t\t<\/div>\n\t\t\t\t<\/div>\n\t\t\t\t\t<\/div>\n\t\t<\/div>\n\t\t\t\t\t<\/div>\n\t\t<\/section>\n\t\t\t\t<section class=\"elementor-section elementor-top-section elementor-element elementor-element-ea205cb elementor-section-boxed elementor-section-height-default elementor-section-height-default wpr-particle-no wpr-jarallax-no wpr-parallax-no wpr-sticky-section-no\" data-id=\"ea205cb\" data-element_type=\"section\">\n\t\t\t\t\t\t<div class=\"elementor-container elementor-column-gap-default\">\n\t\t\t\t\t<div class=\"elementor-column elementor-col-100 elementor-top-column elementor-element elementor-element-37761df\" data-id=\"37761df\" data-element_type=\"column\">\n\t\t\t<div class=\"elementor-widget-wrap elementor-element-populated\">\n\t\t\t\t\t\t<div class=\"elementor-element elementor-element-6d09b4b elementor-widget elementor-widget-text-editor\" data-id=\"6d09b4b\" data-element_type=\"widget\" data-widget_type=\"text-editor.default\">\n\t\t\t\t<div class=\"elementor-widget-container\">\n\t\t\t\t\t\t\t\t\t<ul><li><strong>Gilead Sciences<\/strong>\u00a0announces acquisition of\u00a0<strong>CymaBay Therapeutics<\/strong>\u00a0for\u00a0<strong>$4.3 billion<\/strong>, bolstering its liver disease treatment offerings.<\/li><li><strong>Seladelpar<\/strong>, CymaBay\u2019s lead product candidate for\u00a0<strong>primary biliary cholangitis (PBC)<\/strong>, set to complement Gilead\u2019s portfolio, with FDA priority review underway.<\/li><li>Transaction expected to\u00a0<strong>close in the first quarter of 2024<\/strong>, subject to regulatory approvals, enhancing Gilead&#8217;s revenue growth and EPS by 2025.<\/li><\/ul><p><b>Source:\u00a0<\/b><a href=\"https:\/\/www.businesswire.com\/news\/home\/20240213672000\/en\/Areteia-Therapeutics-Announces-Additional-75MM-in-Series-A-Financing-for-Oral-Dexpramipexole-in-Eosinophilic-Asthma\">Business Wire<\/a><\/p>\t\t\t\t\t\t\t\t<\/div>\n\t\t\t\t<\/div>\n\t\t\t\t\t<\/div>\n\t\t<\/div>\n\t\t\t\t\t<\/div>\n\t\t<\/section>\n\t\t\t\t<section class=\"elementor-section elementor-top-section elementor-element elementor-element-e90ba87 elementor-section-boxed elementor-section-height-default elementor-section-height-default wpr-particle-no wpr-jarallax-no wpr-parallax-no wpr-sticky-section-no\" data-id=\"e90ba87\" data-element_type=\"section\">\n\t\t\t\t\t\t<div class=\"elementor-container elementor-column-gap-default\">\n\t\t\t\t\t<div class=\"elementor-column elementor-col-100 elementor-top-column elementor-element elementor-element-0c976b7\" data-id=\"0c976b7\" data-element_type=\"column\">\n\t\t\t<div class=\"elementor-widget-wrap elementor-element-populated\">\n\t\t\t\t\t\t<div class=\"elementor-element elementor-element-5516a40 elementor-widget elementor-widget-heading\" data-id=\"5516a40\" data-element_type=\"widget\" data-widget_type=\"heading.default\">\n\t\t\t\t<div class=\"elementor-widget-container\">\n\t\t\t\t\t<h2 id=\"notable-quotes\" class=\"elementor-heading-title elementor-size-default\">Notable Quotes<\/h2>\t\t\t\t<\/div>\n\t\t\t\t<\/div>\n\t\t\t\t\t<\/div>\n\t\t<\/div>\n\t\t\t\t\t<\/div>\n\t\t<\/section>\n\t\t\t\t<section class=\"elementor-section elementor-top-section elementor-element elementor-element-d697cb9 elementor-section-boxed elementor-section-height-default elementor-section-height-default wpr-particle-no wpr-jarallax-no wpr-parallax-no wpr-sticky-section-no\" data-id=\"d697cb9\" data-element_type=\"section\">\n\t\t\t\t\t\t<div class=\"elementor-container elementor-column-gap-default\">\n\t\t\t\t\t<div class=\"elementor-column elementor-col-100 elementor-top-column elementor-element elementor-element-0a4aada\" data-id=\"0a4aada\" data-element_type=\"column\">\n\t\t\t<div class=\"elementor-widget-wrap elementor-element-populated\">\n\t\t\t\t\t\t<div class=\"elementor-element elementor-element-91b3c7e elementor-widget elementor-widget-text-editor\" data-id=\"91b3c7e\" data-element_type=\"widget\" data-widget_type=\"text-editor.default\">\n\t\t\t\t<div class=\"elementor-widget-container\">\n\t\t\t\t\t\t\t\t\t<ul><li>\u201cToday\u2019s agreement with Gilead is the culmination of years of focus and determination at CymaBay to advance seladelpar and bring new hope to people living with PBC and their families,\u201d\u00a0<strong>&#8211; Sujal Shah, President and CEO at CymaBay Therapeutics<\/strong><\/li><li>\u201cWe are looking forward to advancing seladelpar by leveraging Gilead\u2019s long-standing expertise in treating and curing liver diseases,\u201d\u00a0<strong>&#8211; Daniel O\u2019Day, Chairman and CEO at Gilead Sciences<\/strong><\/li><\/ul>\t\t\t\t\t\t\t\t<\/div>\n\t\t\t\t<\/div>\n\t\t\t\t\t<\/div>\n\t\t<\/div>\n\t\t\t\t\t<\/div>\n\t\t<\/section>\n\t\t\t\t<section class=\"elementor-section elementor-top-section elementor-element elementor-element-de5db98 elementor-section-boxed elementor-section-height-default elementor-section-height-default wpr-particle-no wpr-jarallax-no wpr-parallax-no wpr-sticky-section-no\" data-id=\"de5db98\" data-element_type=\"section\">\n\t\t\t\t\t\t<div class=\"elementor-container elementor-column-gap-default\">\n\t\t\t\t\t<div class=\"elementor-column elementor-col-100 elementor-top-column elementor-element elementor-element-49139f5\" data-id=\"49139f5\" data-element_type=\"column\">\n\t\t\t<div class=\"elementor-widget-wrap elementor-element-populated\">\n\t\t\t\t\t\t<div class=\"elementor-element elementor-element-416ad5a elementor-widget elementor-widget-heading\" data-id=\"416ad5a\" data-element_type=\"widget\" data-widget_type=\"heading.default\">\n\t\t\t\t<div class=\"elementor-widget-container\">\n\t\t\t\t\t<h2 id=\"sohcs-take\" class=\"elementor-heading-title elementor-size-default\">SoHC's Take<\/h2>\t\t\t\t<\/div>\n\t\t\t\t<\/div>\n\t\t\t\t\t<\/div>\n\t\t<\/div>\n\t\t\t\t\t<\/div>\n\t\t<\/section>\n\t\t\t\t<section class=\"elementor-section elementor-top-section elementor-element elementor-element-815da73 elementor-section-boxed elementor-section-height-default elementor-section-height-default wpr-particle-no wpr-jarallax-no wpr-parallax-no wpr-sticky-section-no\" data-id=\"815da73\" data-element_type=\"section\">\n\t\t\t\t\t\t<div class=\"elementor-container elementor-column-gap-default\">\n\t\t\t\t\t<div class=\"elementor-column elementor-col-100 elementor-top-column elementor-element elementor-element-123f65b\" data-id=\"123f65b\" data-element_type=\"column\">\n\t\t\t<div class=\"elementor-widget-wrap elementor-element-populated\">\n\t\t\t\t\t\t<div class=\"elementor-element elementor-element-e1455ae elementor-widget elementor-widget-text-editor\" data-id=\"e1455ae\" data-element_type=\"widget\" data-widget_type=\"text-editor.default\">\n\t\t\t\t<div class=\"elementor-widget-container\">\n\t\t\t\t\t\t\t\t\t<p>This acquisition marks a significant milestone for both Gilead Sciences and CymaBay Therapeutics, showcasing a strategic move to enhance Gilead&#8217;s liver disease portfolio through the addition of seladelpar, an investigational treatment for primary biliary cholangitis (PBC). This move not only highlights Gilead&#8217;s continued commitment to addressing unmet medical needs in liver diseases but also represents a critical step towards bringing new therapeutic options to patients suffering from PBC, a rare, chronic liver condition primarily affecting women.<\/p><p>The financial and strategic implications of this deal underscore the high stakes in the biopharmaceutical industry for innovative treatments that offer potential breakthroughs in care. With seladelpar&#8217;s promising clinical trial results and the ongoing FDA priority review, this acquisition is poised to significantly contribute to Gilead&#8217;s growth and position in the market as a leader in liver disease therapeutics. Furthermore, the collaboration between Gilead&#8217;s extensive regulatory and commercial expertise and CymaBay&#8217;s pioneering research efforts is expected to accelerate the development and availability of seladelpar to patients in need, reflecting a shared commitment to improving patient outcomes and quality of life.<\/p>\t\t\t\t\t\t\t\t<\/div>\n\t\t\t\t<\/div>\n\t\t\t\t\t<\/div>\n\t\t<\/div>\n\t\t\t\t\t<\/div>\n\t\t<\/section>\n\t\t<div class=\"elementor-element elementor-element-ea8e122 e-flex e-con-boxed wpr-particle-no wpr-jarallax-no wpr-parallax-no wpr-sticky-section-no e-con e-parent\" data-id=\"ea8e122\" data-element_type=\"container\">\n\t\t\t\t\t<div class=\"e-con-inner\">\n\t\t\t\t\t<\/div>\n\t\t\t\t<\/div>\n\t\t\t\t<\/div>\n\t\t","protected":false},"excerpt":{"rendered":"Key Highlights Gilead Sciences\u00a0announces acquisition of\u00a0CymaBay Therapeutics\u00a0for\u00a0$4.3 billion, bolstering its liver disease treatment offerings. Seladelpar, CymaBay\u2019s lead product&hellip;\n","protected":false},"author":14,"featured_media":19742,"comment_status":"closed","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"nf_dc_page":"","pgc_sgb_lightbox_settings":"","_jetpack_memberships_contains_paid_content":false,"footnotes":""},"categories":[1900,1896],"tags":[4728,4730,4729,4727,4731],"class_list":["post-19740","post","type-post","status-publish","format-standard","has-post-thumbnail","category-ma-news","category-news","tag-cymabay-therapeutics-inc","tag-daniel-oday","tag-food-and-drug-administration-fda","tag-gilead-sciences-inc","tag-sujal-shah","cs-entry","cs-video-wrap"],"yoast_head":"<!-- This site is optimized with the Yoast SEO Premium plugin v22.6 (Yoast SEO v24.6) - https:\/\/yoast.com\/wordpress\/plugins\/seo\/ -->\n<title>Gilead Acquires CymaBay in $4.3 Billion Deal<\/title>\n<meta name=\"description\" content=\"Gilead Sciences to acquire CymaBay Therapeutics for $32.50 per share, enhancing its liver disease portfolio with promising PBC treatment, seladelpar.\" \/>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/sliceofhealthcare.com\/gilead-acquires-cymabay-in-4-3-billion-deal\/\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Gilead Acquires CymaBay in $4.3 Billion Deal\" \/>\n<meta property=\"og:description\" content=\"Gilead Sciences to acquire CymaBay Therapeutics for $32.50 per share, enhancing its liver disease portfolio with promising PBC treatment, seladelpar.\" \/>\n<meta property=\"og:url\" content=\"https:\/\/sliceofhealthcare.com\/gilead-acquires-cymabay-in-4-3-billion-deal\/\" \/>\n<meta property=\"og:site_name\" content=\"Slice of Healthcare\" \/>\n<meta property=\"article:published_time\" content=\"2024-02-23T06:00:06+00:00\" \/>\n<meta property=\"article:modified_time\" content=\"2024-02-23T06:39:20+00:00\" \/>\n<meta property=\"og:image\" content=\"http:\/\/sliceofhealthcare.com\/wp-content\/uploads\/2024\/02\/Gilead-Acquires-CymaBay-in-_4.3-Billion-Deal.png\" \/>\n\t<meta property=\"og:image:width\" content=\"1280\" \/>\n\t<meta property=\"og:image:height\" content=\"720\" \/>\n\t<meta property=\"og:image:type\" content=\"image\/png\" \/>\n<meta name=\"author\" content=\"Chris-Anne Roque\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:creator\" content=\"@SliceofHC\" \/>\n<meta name=\"twitter:site\" content=\"@SliceofHC\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"Chris-Anne Roque\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"2 minutes\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\/\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\/\/sliceofhealthcare.com\/gilead-acquires-cymabay-in-4-3-billion-deal\/#article\",\"isPartOf\":{\"@id\":\"https:\/\/sliceofhealthcare.com\/gilead-acquires-cymabay-in-4-3-billion-deal\/\"},\"author\":{\"name\":\"Chris-Anne Roque\",\"@id\":\"https:\/\/sliceofhealthcare.com\/#\/schema\/person\/3e92e4d38084087254b8ad198e76e6ca\"},\"headline\":\"Gilead Acquires CymaBay in $4.3 Billion Deal\",\"datePublished\":\"2024-02-23T06:00:06+00:00\",\"dateModified\":\"2024-02-23T06:39:20+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\/\/sliceofhealthcare.com\/gilead-acquires-cymabay-in-4-3-billion-deal\/\"},\"wordCount\":325,\"publisher\":{\"@id\":\"https:\/\/sliceofhealthcare.com\/#organization\"},\"image\":{\"@id\":\"https:\/\/sliceofhealthcare.com\/gilead-acquires-cymabay-in-4-3-billion-deal\/#primaryimage\"},\"thumbnailUrl\":\"https:\/\/i0.wp.com\/sliceofhealthcare.com\/wp-content\/uploads\/2024\/02\/Gilead-Acquires-CymaBay-in-_4.3-Billion-Deal.png?fit=1280%2C720&ssl=1\",\"keywords\":[\"CymaBay Therapeutics Inc\",\"Daniel O\u2019Day\",\"Food and Drug Administration (FDA)\",\"Gilead Sciences Inc\",\"Sujal Shah\"],\"articleSection\":[\"M&amp;A News\",\"News\"],\"inLanguage\":\"en-US\"},{\"@type\":\"WebPage\",\"@id\":\"https:\/\/sliceofhealthcare.com\/gilead-acquires-cymabay-in-4-3-billion-deal\/\",\"url\":\"https:\/\/sliceofhealthcare.com\/gilead-acquires-cymabay-in-4-3-billion-deal\/\",\"name\":\"Gilead Acquires CymaBay in $4.3 Billion Deal\",\"isPartOf\":{\"@id\":\"https:\/\/sliceofhealthcare.com\/#website\"},\"primaryImageOfPage\":{\"@id\":\"https:\/\/sliceofhealthcare.com\/gilead-acquires-cymabay-in-4-3-billion-deal\/#primaryimage\"},\"image\":{\"@id\":\"https:\/\/sliceofhealthcare.com\/gilead-acquires-cymabay-in-4-3-billion-deal\/#primaryimage\"},\"thumbnailUrl\":\"https:\/\/i0.wp.com\/sliceofhealthcare.com\/wp-content\/uploads\/2024\/02\/Gilead-Acquires-CymaBay-in-_4.3-Billion-Deal.png?fit=1280%2C720&ssl=1\",\"datePublished\":\"2024-02-23T06:00:06+00:00\",\"dateModified\":\"2024-02-23T06:39:20+00:00\",\"description\":\"Gilead Sciences to acquire CymaBay Therapeutics for $32.50 per share, enhancing its liver disease portfolio with promising PBC treatment, seladelpar.\",\"breadcrumb\":{\"@id\":\"https:\/\/sliceofhealthcare.com\/gilead-acquires-cymabay-in-4-3-billion-deal\/#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\/\/sliceofhealthcare.com\/gilead-acquires-cymabay-in-4-3-billion-deal\/\"]}]},{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\/\/sliceofhealthcare.com\/gilead-acquires-cymabay-in-4-3-billion-deal\/#primaryimage\",\"url\":\"https:\/\/i0.wp.com\/sliceofhealthcare.com\/wp-content\/uploads\/2024\/02\/Gilead-Acquires-CymaBay-in-_4.3-Billion-Deal.png?fit=1280%2C720&ssl=1\",\"contentUrl\":\"https:\/\/i0.wp.com\/sliceofhealthcare.com\/wp-content\/uploads\/2024\/02\/Gilead-Acquires-CymaBay-in-_4.3-Billion-Deal.png?fit=1280%2C720&ssl=1\",\"width\":1280,\"height\":720},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\/\/sliceofhealthcare.com\/gilead-acquires-cymabay-in-4-3-billion-deal\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\/\/sliceofhealthcare.com\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"Gilead Acquires CymaBay in $4.3 Billion Deal\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\/\/sliceofhealthcare.com\/#website\",\"url\":\"https:\/\/sliceofhealthcare.com\/\",\"name\":\"Slice of Healthcare\",\"description\":\"Redefining Healthcare Media.\",\"publisher\":{\"@id\":\"https:\/\/sliceofhealthcare.com\/#organization\"},\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\/\/sliceofhealthcare.com\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"},{\"@type\":\"Organization\",\"@id\":\"https:\/\/sliceofhealthcare.com\/#organization\",\"name\":\"Slice of Healthcare\",\"url\":\"https:\/\/sliceofhealthcare.com\/\",\"logo\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\/\/sliceofhealthcare.com\/#\/schema\/logo\/image\/\",\"url\":\"https:\/\/i0.wp.com\/sliceofhealthcare.com\/wp-content\/uploads\/2022\/02\/New-large-logo-for-slice-of-healthcare-website-2x-160-%C3%97-160-px.png?fit=160%2C160&ssl=1\",\"contentUrl\":\"https:\/\/i0.wp.com\/sliceofhealthcare.com\/wp-content\/uploads\/2022\/02\/New-large-logo-for-slice-of-healthcare-website-2x-160-%C3%97-160-px.png?fit=160%2C160&ssl=1\",\"width\":160,\"height\":160,\"caption\":\"Slice of Healthcare\"},\"image\":{\"@id\":\"https:\/\/sliceofhealthcare.com\/#\/schema\/logo\/image\/\"},\"sameAs\":[\"https:\/\/x.com\/SliceofHC\"]},{\"@type\":\"Person\",\"@id\":\"https:\/\/sliceofhealthcare.com\/#\/schema\/person\/3e92e4d38084087254b8ad198e76e6ca\",\"name\":\"Chris-Anne Roque\",\"image\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\/\/sliceofhealthcare.com\/#\/schema\/person\/image\/\",\"url\":\"https:\/\/secure.gravatar.com\/avatar\/3175699e8136e462915e1ca2c0407ee6?s=96&d=mm&r=g\",\"contentUrl\":\"https:\/\/secure.gravatar.com\/avatar\/3175699e8136e462915e1ca2c0407ee6?s=96&d=mm&r=g\",\"caption\":\"Chris-Anne Roque\"},\"url\":\"https:\/\/sliceofhealthcare.com\/author\/anne\/\"}]}<\/script>\n<!-- \/ Yoast SEO Premium plugin. -->","yoast_head_json":{"title":"Gilead Acquires CymaBay in $4.3 Billion Deal","description":"Gilead Sciences to acquire CymaBay Therapeutics for $32.50 per share, enhancing its liver disease portfolio with promising PBC treatment, seladelpar.","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/sliceofhealthcare.com\/gilead-acquires-cymabay-in-4-3-billion-deal\/","og_locale":"en_US","og_type":"article","og_title":"Gilead Acquires CymaBay in $4.3 Billion Deal","og_description":"Gilead Sciences to acquire CymaBay Therapeutics for $32.50 per share, enhancing its liver disease portfolio with promising PBC treatment, seladelpar.","og_url":"https:\/\/sliceofhealthcare.com\/gilead-acquires-cymabay-in-4-3-billion-deal\/","og_site_name":"Slice of Healthcare","article_published_time":"2024-02-23T06:00:06+00:00","article_modified_time":"2024-02-23T06:39:20+00:00","og_image":[{"width":1280,"height":720,"url":"http:\/\/sliceofhealthcare.com\/wp-content\/uploads\/2024\/02\/Gilead-Acquires-CymaBay-in-_4.3-Billion-Deal.png","type":"image\/png"}],"author":"Chris-Anne Roque","twitter_card":"summary_large_image","twitter_creator":"@SliceofHC","twitter_site":"@SliceofHC","twitter_misc":{"Written by":"Chris-Anne Roque","Est. reading time":"2 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/sliceofhealthcare.com\/gilead-acquires-cymabay-in-4-3-billion-deal\/#article","isPartOf":{"@id":"https:\/\/sliceofhealthcare.com\/gilead-acquires-cymabay-in-4-3-billion-deal\/"},"author":{"name":"Chris-Anne Roque","@id":"https:\/\/sliceofhealthcare.com\/#\/schema\/person\/3e92e4d38084087254b8ad198e76e6ca"},"headline":"Gilead Acquires CymaBay in $4.3 Billion Deal","datePublished":"2024-02-23T06:00:06+00:00","dateModified":"2024-02-23T06:39:20+00:00","mainEntityOfPage":{"@id":"https:\/\/sliceofhealthcare.com\/gilead-acquires-cymabay-in-4-3-billion-deal\/"},"wordCount":325,"publisher":{"@id":"https:\/\/sliceofhealthcare.com\/#organization"},"image":{"@id":"https:\/\/sliceofhealthcare.com\/gilead-acquires-cymabay-in-4-3-billion-deal\/#primaryimage"},"thumbnailUrl":"https:\/\/i0.wp.com\/sliceofhealthcare.com\/wp-content\/uploads\/2024\/02\/Gilead-Acquires-CymaBay-in-_4.3-Billion-Deal.png?fit=1280%2C720&ssl=1","keywords":["CymaBay Therapeutics Inc","Daniel O\u2019Day","Food and Drug Administration (FDA)","Gilead Sciences Inc","Sujal Shah"],"articleSection":["M&amp;A News","News"],"inLanguage":"en-US"},{"@type":"WebPage","@id":"https:\/\/sliceofhealthcare.com\/gilead-acquires-cymabay-in-4-3-billion-deal\/","url":"https:\/\/sliceofhealthcare.com\/gilead-acquires-cymabay-in-4-3-billion-deal\/","name":"Gilead Acquires CymaBay in $4.3 Billion Deal","isPartOf":{"@id":"https:\/\/sliceofhealthcare.com\/#website"},"primaryImageOfPage":{"@id":"https:\/\/sliceofhealthcare.com\/gilead-acquires-cymabay-in-4-3-billion-deal\/#primaryimage"},"image":{"@id":"https:\/\/sliceofhealthcare.com\/gilead-acquires-cymabay-in-4-3-billion-deal\/#primaryimage"},"thumbnailUrl":"https:\/\/i0.wp.com\/sliceofhealthcare.com\/wp-content\/uploads\/2024\/02\/Gilead-Acquires-CymaBay-in-_4.3-Billion-Deal.png?fit=1280%2C720&ssl=1","datePublished":"2024-02-23T06:00:06+00:00","dateModified":"2024-02-23T06:39:20+00:00","description":"Gilead Sciences to acquire CymaBay Therapeutics for $32.50 per share, enhancing its liver disease portfolio with promising PBC treatment, seladelpar.","breadcrumb":{"@id":"https:\/\/sliceofhealthcare.com\/gilead-acquires-cymabay-in-4-3-billion-deal\/#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/sliceofhealthcare.com\/gilead-acquires-cymabay-in-4-3-billion-deal\/"]}]},{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/sliceofhealthcare.com\/gilead-acquires-cymabay-in-4-3-billion-deal\/#primaryimage","url":"https:\/\/i0.wp.com\/sliceofhealthcare.com\/wp-content\/uploads\/2024\/02\/Gilead-Acquires-CymaBay-in-_4.3-Billion-Deal.png?fit=1280%2C720&ssl=1","contentUrl":"https:\/\/i0.wp.com\/sliceofhealthcare.com\/wp-content\/uploads\/2024\/02\/Gilead-Acquires-CymaBay-in-_4.3-Billion-Deal.png?fit=1280%2C720&ssl=1","width":1280,"height":720},{"@type":"BreadcrumbList","@id":"https:\/\/sliceofhealthcare.com\/gilead-acquires-cymabay-in-4-3-billion-deal\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/sliceofhealthcare.com\/"},{"@type":"ListItem","position":2,"name":"Gilead Acquires CymaBay in $4.3 Billion Deal"}]},{"@type":"WebSite","@id":"https:\/\/sliceofhealthcare.com\/#website","url":"https:\/\/sliceofhealthcare.com\/","name":"Slice of Healthcare","description":"Redefining Healthcare Media.","publisher":{"@id":"https:\/\/sliceofhealthcare.com\/#organization"},"potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/sliceofhealthcare.com\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Organization","@id":"https:\/\/sliceofhealthcare.com\/#organization","name":"Slice of Healthcare","url":"https:\/\/sliceofhealthcare.com\/","logo":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/sliceofhealthcare.com\/#\/schema\/logo\/image\/","url":"https:\/\/i0.wp.com\/sliceofhealthcare.com\/wp-content\/uploads\/2022\/02\/New-large-logo-for-slice-of-healthcare-website-2x-160-%C3%97-160-px.png?fit=160%2C160&ssl=1","contentUrl":"https:\/\/i0.wp.com\/sliceofhealthcare.com\/wp-content\/uploads\/2022\/02\/New-large-logo-for-slice-of-healthcare-website-2x-160-%C3%97-160-px.png?fit=160%2C160&ssl=1","width":160,"height":160,"caption":"Slice of Healthcare"},"image":{"@id":"https:\/\/sliceofhealthcare.com\/#\/schema\/logo\/image\/"},"sameAs":["https:\/\/x.com\/SliceofHC"]},{"@type":"Person","@id":"https:\/\/sliceofhealthcare.com\/#\/schema\/person\/3e92e4d38084087254b8ad198e76e6ca","name":"Chris-Anne Roque","image":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/sliceofhealthcare.com\/#\/schema\/person\/image\/","url":"https:\/\/secure.gravatar.com\/avatar\/3175699e8136e462915e1ca2c0407ee6?s=96&d=mm&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/3175699e8136e462915e1ca2c0407ee6?s=96&d=mm&r=g","caption":"Chris-Anne Roque"},"url":"https:\/\/sliceofhealthcare.com\/author\/anne\/"}]}},"jetpack_featured_media_url":"https:\/\/i0.wp.com\/sliceofhealthcare.com\/wp-content\/uploads\/2024\/02\/Gilead-Acquires-CymaBay-in-_4.3-Billion-Deal.png?fit=1280%2C720&ssl=1","jetpack-related-posts":[],"jetpack_sharing_enabled":true,"_links":{"self":[{"href":"https:\/\/sliceofhealthcare.com\/wp-json\/wp\/v2\/posts\/19740","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/sliceofhealthcare.com\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/sliceofhealthcare.com\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/sliceofhealthcare.com\/wp-json\/wp\/v2\/users\/14"}],"replies":[{"embeddable":true,"href":"https:\/\/sliceofhealthcare.com\/wp-json\/wp\/v2\/comments?post=19740"}],"version-history":[{"count":5,"href":"https:\/\/sliceofhealthcare.com\/wp-json\/wp\/v2\/posts\/19740\/revisions"}],"predecessor-version":[{"id":19817,"href":"https:\/\/sliceofhealthcare.com\/wp-json\/wp\/v2\/posts\/19740\/revisions\/19817"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/sliceofhealthcare.com\/wp-json\/wp\/v2\/media\/19742"}],"wp:attachment":[{"href":"https:\/\/sliceofhealthcare.com\/wp-json\/wp\/v2\/media?parent=19740"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/sliceofhealthcare.com\/wp-json\/wp\/v2\/categories?post=19740"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/sliceofhealthcare.com\/wp-json\/wp\/v2\/tags?post=19740"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}